Objectives: To analyze predictive clinical factors of survival in bone-metastatic prostate cancer, and to develop a prognostic nomogram for patients with this condition.
Methods: The present study included 392 patients with bone-metastatic prostate cancer treated with androgen deprivation therapy. Pretreatment parameters were analyzed using the Cox proportional hazards model to identify the predictors of overall survival. Covariates - which showed statistical significance on multivariate analysis - were used to develop a nomogram. A linear predictor model was utilized to develop the nomogram.
Results: The median overall survival was 40.3 months (95% confidence interval 32.2-48.5). Univariate analysis showed that clinical T stage, Gleason score, initial prostate-specific antigen value and the number of metastatic lesions were independent prognostic factors for overall survival. These predictors remained significant as independent prognostic factors for overall survival after analysis using the multivariate Cox regression model. The nomogram constructed from those prognostic factors showed good discrimination for predicting the 5-year overall survival, with an area under the curve of 0.69. Acceptable agreement of the observed and predicted probabilities was observed in the calibration plot.
Conclusions: The present prognostic nomogram might be a useful tool for predicting overall survival in pretreatment bone-metastatic prostate cancer, specifically among Indonesian patients. Further studies are required to provide external validation to support the utilization of this nomogram.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/iju.13813 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Thermal Ablation with MRgFUS: From Physics to Oncological Applications.
Cancers (Basel)
December 2024
Department of Diagnostic Imaging, Oncologic Radiotherapy and Hematology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00100 Rome, Italy.
The growing interest in minimal and non-invasive therapies, especially in the field of cancer treatment, highlights a significant shift toward safer and more effective options. Ablative therapies are well-established tools in cancer treatment, with known effects including locoregional control, while their role as modulators of the systemic immune response against cancer is emerging. The HIFU developed with magnetic resonance imaging (MRI) guidance enables treatment precision, improves real-time procedural control, and ensures accurate outcome assessment.
View Article and Find Full Text PDFAsymptomatic Hypocalcemia Related to Denosumab Administration in Bone-Metastatic Patient Affected by Colorectal Cancer: A Case Report.
Endocr Metab Immune Disord Drug Targets
December 2024
Unicamillus-Saint Camillus International University of Health Sciences, Rome, Italy.
Background: Denosumab, a fully humanized monoclonal neutralizing antibody inhibiting the RANK/RANKL/OPG signaling pathway, is widely used for treating patients with bone metastases. However, its use in cancer patients with bone metastases is burdened by the risk of all grades of hypocalcemia, with the severe grade being rare. In the literature, several cases of severe symptomatic hypocalcemia have been reported, particularly in patients with breast and prostate cancers.
View Article and Find Full Text PDFOsteoblast-derived exosomal miR-140-3p targets ACER2 and increases the progression of prostate cancer via the AKT/mTOR pathway-mediated inhibition of autophagy.
FASEB J
December 2024
Department of Organ Transplant, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Advanced prostate cancer (aPCa) often results in bone metastases (BM). However, the mechanism underlying its progression and metastasis to bones remains unclear. Therefore, we examined whether exosomal miR-140-3p affects prostate cancer (PCa) progression.
View Article and Find Full Text PDFOsteoblast-Derived ECM1 Promotes Anti-Androgen Resistance in Bone Metastatic Prostate Cancer.
Adv Sci (Weinh)
January 2025
Department of Orthopedic Surgery, the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510080, China.
Acquired resistance to hormonal therapy, particularly enzalutamide (ENZ), remains a significant obstacle in the treatment of advanced bone metastatic prostate cancer. Here, it is demonstrated that under ENZ treatment, osteoblasts in the bone microenvironment secrete increased levels of extracellular matrix protein 1 (ECM1), which affects surrounding prostate cancer cells, promoting tumor cell proliferation and anti-androgen resistance. Mechanistically, ECM1 interacts with the enolase 1 (ENO1) receptor on the prostate cancer cell membrane, leading to its phosphorylation at the Y189 site.
View Article and Find Full Text PDFA switch from lysosomal degradation to secretory autophagy initiates osteogenic bone metastasis in prostate cancer.
J Extracell Vesicles
November 2024
Department of Orthopedics, Southwest Hospital, Third Military Medical University, Chongqing, China.
The identification of both autophagy-related material degradation and unconventional secretion has paved the way for significant breakthroughs linking autophagy to a plethora of physiological processes and disease conditions. However, the mechanisms that coordinate these two pathways remain elusive. Here, we demonstrate that a switch from the lysosomal degradation to a secretory autophagy pathway is governed by protein tyrosine phosphatase 1B (PTP1B, encoded by PTPN1).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!